Healthleap Builds a Clinical Safety Net for Hospitals

Jemima Meyer did not begin with a plan to build a hospital AI platform. She began with the work in front of her as a clinical dietitian: too many records to review, too little time, and patients whose nutrition risk could remain invisible until the consequences became harder to reverse.

Healthleap grew from that operating reality. Founded by siblings Jemima Meyer and Josiah Meyer, the San Francisco-based company analyzes hospital electronic health records and places risk scores inside existing clinical workflows so care teams can prioritize patients for review. Malnutrition is the validated starting condition; the larger ambition is a clinical safety net for conditions hospitals routinely miss.

Healthleap matters now because hospitals already have enormous amounts of data. The scarce resource is timely attention. The company is building around the handoff between what the record contains and when the right clinician can act on it.

About Healthleap

Healthleap's current company story begins in South Africa in 2022, after Jemima Meyer built NutriLeap to help fellow dietitians work faster. Josiah Meyer, now co-founder and CEO, partnered with his sister to turn that specialty tool into a broader company. Their founding logic was simple enough to survive the expansion: software should read at scale so clinicians can spend judgment where it matters.

The company has since moved its center of gravity to San Francisco and built a roughly 25-person team. Richard Riggs, MD, serves as Chief Medical Officer after previously holding that role at Cedars-Sinai. The team combines clinical, data, engineering, implementation, and commercial work because the product has to live inside both medicine and hospital operations.

Healthleap's mission is to make sure no patient who can be helped slips through unseen. That language carries an important product constraint. The platform is not designed to replace diagnosis or clinical judgment. It is designed to change the order in which limited human attention reaches the patient list.

The Problem Healthleap Is Solving

Hospital records do not arrive as one clean story. Lab results, vital signs, weights, medications, diagnoses, orders, and clinician notes accumulate across different fields and moments. A sign such as poor appetite, muscle loss, or difficulty swallowing may be present without becoming an obvious priority for an already stretched team.

Healthleap connects to the EHR, analyzes structured and unstructured information, and writes a risk score into the care team's existing workflow each morning. Higher-risk patients move toward the top of the list, where a clinician can investigate. The software identifies a reason to look closer; it does not make the diagnosis.

That workflow position is commercially important. Hospitals have no shortage of dashboards asking for attention. Healthleap has to make its signal useful inside the systems clinicians already use, with enough precision and explanation to justify another intervention in a high-stakes environment.

Evidence Behind the Malnutrition Platform

Healthleap's strongest validation is in malnutrition screening. A 2025 Applied Clinical Informatics study evaluated more than 166,000 admissions from more than 106,000 patients over 3.75 years. The company reports 0.92 AUROC on day one and 0.95 across the hospital stay, with 88% higher sensitivity than the modified Malnutrition Screening Tool and identification a mean of four days earlier than initial dietitian documentation.

Healthleap says it now works across more than 50 hospitals, including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. TechCrunch reported company-reported growth from three hospital partners to more than 50 in the prior year and revenue growth above 10x.

The company's evidence page reports $23.8M in annualized financial impact at one Penn Medicine hospital, including reimbursement and length-of-stay effects. Healthleap also reports $11M in annual impact at Cedars-Sinai. Those figures are partner and deployment results presented by the company, not a universal promise, but they explain why clinical and financial leaders can evaluate the same workflow through different outcomes.

From One Condition to a Broader Safety Net

Malnutrition gives Healthleap a clinically meaningful wedge, not a finished category. The company is building or testing programs for delirium and toxic metabolic encephalopathy, aspiration pneumonia, pressure injuries, and congestive-heart-failure readmission risk. CEO Josiah Meyer has described a long-term goal of covering more than 40 major conditions and eventually extending into outpatient and home care.

Each expansion creates a new evidence obligation. The data pattern changes, the clinical reference standard changes, the responsible care team changes, and the consequence of a missed or noisy signal changes. Healthleap cannot treat validation in malnutrition as a transferable permission slip for every adjacent condition.

That is also where the company can build a durable advantage. EHR integration, condition-specific models, published evidence, implementation discipline, customer outcomes, and clinical trust compound slowly. A model can be copied more easily than a product that survives procurement, integration, workflow change, clinical scrutiny, and finance review across dozens of health systems.

Funding and Market Momentum

Healthleap has disclosed $39.1M in financing. Fifty Years led a $1.1M pre-seed announced in 2022. In October 2026, the company announced an $8M Seed co-led by Sequoia Capital and First Round Capital and a $30M Series A led by Hummingbird Ventures.

The capital is funding engineering, product, sales, customer success, and the work required to add more conditions. The financing follows company-reported expansion across hospital systems and a commercial model that can tie contract value to measurable hospital outcomes.

For investors, Healthleap sits at a useful intersection. Hospitals want clinical AI that improves care without creating another disconnected destination, while finance teams want measurable operating impact. The company is trying to satisfy both buyers with the same intervention: earlier prioritization inside the EHR.

Leadership, Culture, and Hiring

Healthleap's careers page describes three operating values: Mission first, Seek truth, and Win together. The language is unusually aligned with the product risk. A clinical AI company needs mission discipline, evidence strong enough to change its own mind, and collaboration across clinicians, engineers, data scientists, customer teams, and hospital partners.

Hiring momentum is therefore more than a recruiting story. Moving from one validated condition to a platform requires research capacity, product and engineering depth, implementation support, customer success, and a commercial team that can sell outcomes without outrunning the evidence.

Healthleap is also hiring into a market where technical talent can choose among louder AI categories with shorter feedback loops. The people who join are choosing work where accuracy, deployment, and trust matter more than a polished demo, and where the final unit of value is a patient receiving attention sooner.

What Healthleap Signals for Healthcare AI

Healthcare AI is moving from generating content toward deciding where human attention should go next. That shift raises the stakes. A useful model must fit the workflow, expose enough evidence to earn trust, and prove that acting on its output improves something a hospital and a patient care about.

Healthleap has built a credible starting record in malnutrition: peer-reviewed validation, more than 50 reported hospital deployments, named health systems, measurable customer outcomes, and fresh capital from Hummingbird Ventures, Sequoia Capital, First Round Capital, and earlier investor Fifty Years.

The broader company will be judged by how well that record travels. Every new condition asks Healthleap to turn scattered chart evidence into a timely clinical priority without flooding teams with noise or borrowing credibility from the first model. The company's safety-net thesis will keep expanding one workflow, one validation study, and one earlier intervention at a time.